by Nicolas Hulscher, MPH

A newly published peer-reviewed study in Gut Microbes has uncovered a previously unknown cancer-fighting bacterium isolated from amphibian and reptile gut microbiomes—delivering results that exceeded modern oncology treatments.

In an immunocompetent mouse model of colorectal cancer, a single intravenous dose of Ewingella americana led to complete tumor elimination in 100% of treated animals, with no recurrence upon re-exposure to cancer cells—suggesting durable, long-term immune protection.

Even more striking, the bacterium outperformed both chemotherapy (doxorubicin, “red devil”) and immune checkpoint blockade (anti–PD-L1)—two pillars of modern cancer therapy.

What makes this discovery particularly compelling is the mechanism. E. americana is not a passive drug—it is a living, tumor-targeting organism. As a facultative anaerobe, it preferentially accumulates within the hypoxic tumor microenvironment, where it rapidly proliferates and exerts direct cytotoxic effects while simultaneously activating a broad immune response. Within hours, tumors become infiltrated with T cells, B cells, and neutrophils, accompanied by surges in key inflammatory cytokines like TNF-α and IFN-γ.

Investigators observed approximately a 3,000-fold increase in bacterial load within tumors within 24 hours, indicating highly efficient tumor homing and intratumoral expansion. This dual-action approach—direct tumor destruction combined with immune activation—distinguishes it fundamentally from conventional therapies, which typically rely on a single mechanism of action.

Equally notable is the safety profile observed in this preclinical model. Despite intravenous administration of live...